Young stroke: An update on epidemiology,emerging risk factors,and future research directions

Abstract

The incidence of ischemic stroke among young adults (aged 18–49 years) has risen over recent decades, particularly in high-income countries, contrasting with the decline seen in older populations. This trend represents a growing public health concern, as stroke at young age often leads to long-term psychosocial consequences and loss of productive life years. The increasing incidence may partly reflect a higher prevalence of traditional vascular risk factors, as well as the identification of non-traditional risk and trigger factors such as air pollution, sleep apnea, long working hours, vigorous exercise, and illicit drug use. Diagnostic evaluation in this young population is typically more extensive than in older patients, given the broad spectrum of potential underlying causes. A structured, multidisciplinary approach integrating vascular, hematologic, and cardiac assessment is essential for accurate etiological classification. Although functional outcomes are generally favorable, many young stroke survivors experience persistent psychosocial sequelae, including cognitive impairment, depression, anxiety, and fatigue, which significantly affect quality of life. Recurrence risk varies according to stroke etiology, with the lowest rates observed in patients with a cryptogenic stroke. These findings highlight the importance of more tailored secondary prevention strategies, as antiplatelet therapy is not without risks. Further research is needed to identify novel risk and trigger factors, refine prognostic tools, optimize secondary prevention, and develop interventions addressing the psychosocial recovery of young stroke survivors.

Keywords

Ischemic stroke in young adults incidence risk factors diagnostics psychosocial sequelae

Introduction

While the incidence of ischemic stroke among older adults has declined over recent decades, the opposite trend is observed among younger people. Adults aged 18 to 49 years are increasingly affected by ischemic stroke, with recent studies showing a consistent rise in incidence across both high- and low-income countries.^1–3 This shift signals a growing public health concern, as stroke at young age may have lifelong consequences, potentially lasting for several decades. Its impact extends beyond the individual, by affecting family dynamics, social relationships and career development. In addition, it has profound societal impact due to loss of economic productivity during what are typically the most active years of life. Stroke at young age often requires a more extensive diagnostic workup due to its diversity of potential causes. Once the underlying etiology is identified, personalized treatment and follow-up are essential. Although functional outcomes are generally favorable, many patients face persistent symptoms such as fatigue, cognitive impairment, and psychological distress that hinder social participation and return to work.^4–8 This more hidden burden highlights the importance of multidisciplinary care approaches that address both medical and psychosocial recovery.

In this issue of the International Journal of Stroke (IJS), we focus on ischemic stroke at young age, highlighting recent advances in the field and presenting novel research that expands our understanding of its etiology and outcomes. Furthermore, we address key challenges and future directions for new research.

Epidemiology: rising stroke incidence among young people

Over the past two decades, advances in both primary and secondary prevention strategies, particularly in high-income countries (HICs), have contributed to a decline in the incidence of ischemic stroke among older adults (⩾55 years).^1,9,10 However, this favorable trend does not extend to younger populations. As highlighted in the review by Nehme and Li¹¹ in this issue of IJS, the incidence of ischemic stroke in individuals under the age of 50 is considerably rising in HICs. Although absolute incidences vary across studies, reflecting differences in methodology, diagnostic criteria and population characteristics, nearly all investigators report increasing incidences in younger compared to older age groups. Some more recent population-based studies suggest that this upward trend may have stabilized in some regions after 2010.

Large-scale studies from Brazil and China have reported increasing stroke incidence among young adults in low- and middle-income countries (LMICs) up to 2015; however, findings from other population-based studies (in LMICs) are conflicting, with some even suggesting a potential decline in incidence in more recent years.^2,3,12,13

Understanding the upward trend

This rising incidence underscores the need for a better understanding of the underlying drivers and risk factors. Identifying these contributors is crucial to developing more tailored and effective prevention strategies that may help reverse this trend. In HICs, part of the observed increase may be attributed to the improvement of diagnostic coding and hospital-based stroke registries.¹⁴

Advancements in neuroimaging, particularly magnetic resonance imaging (MRI) with diffusion-weighted imaging (DWI), have improved the accuracy of ischemic stroke diagnosis. MRI-DWI provides greater sensitivity for detecting ischemia compared to computed tomography (CT), potentially leading to higher detection rates and better differentiation from stroke mimics.^15,16 This may partly explain the observed rise in stroke incidence among young adults.

As reported by Nehme and Li,¹¹ and confirmed in the JACARANDA study by Gonzalez et al.,¹⁷ traditional vascular risk factors are common among young adults with ischemic stroke. Conditions such as hypertension, smoking, obesity, and hyperlipidemia are present in approximately 20–47% of patients within this age group.^18,19 Diabetes and obesity, in particular, have shown a marked upward trend in prevalence. Yet, preventive strategies remain limited as current risk prediction models heavily rely on age, leaving younger individuals often undertreated. Still, rising incidence of ischemic stroke has also been observed in individuals without these traditional risk factors, suggesting that atherosclerosis alone cannot explain this trend. This points toward additional, yet partially unknown underlying mechanisms.

Identification of novel risk factors

Beyond traditional vascular risk factors, several non-traditional contributors have been linked to the rising incidence of ischemic stroke among young adults. Environmental and lifestyle-related exposures, such as air pollution, have been associated with an elevated cardiovascular risk, particularly in individuals under 55 years of age.^20–22 Moreover, factors like long working hours (>40 hours per week), low physical activity levels, and both acute and chronic psychosocial stress may further increase stroke risk at younger ages, as discussed by Nehme and Li¹¹ in this issue. In contrast to low physical activity levels, vigorous exercise has also been identified as a potential trigger for stroke in young adults, as have sexual activity and flu-like diseases.²³

The growing prevalence of illicit drug use among young people is a serious concern worldwide and contributes to an increased risk of stroke in younger populations. Particularly cocaine and amphetamines elevate stroke risk through mechanisms including hypertension, vasospasm, endothelial dysfunction, cardiomyopathy and, less commonly, cerebral vasculitis.^24,25

A study by Deb et al.²⁶ published in this issue identifies additional risk factors for early-onset stroke, including chronic kidney disease, cancer, sleep apnea, and bipolar disorder. The authors also report associations with non-white race, Hispanic ethnicity—possibly reflecting a greater burden of cardiovascular risk factors—and non-partnered status, further underscoring the multifactorial nature of stroke in young adults.

Regarding malignancy, patients with active cancer are at increased risk of ischemic stroke due to direct tumor effects, cancer-associated hypercoagulability, and treatment-related complications. Recent research reports a threefold to fivefold increased risk of cancer diagnosis within the first year after stroke in patients aged 15–49 compared to age-matched controls.²⁷

In addition, a recent study indicates that pregnancy complications are linked to a higher risk of ischemic stroke in young women, especially strokes due to atherosclerosis. This emphasizes the elevated cardiovascular risk among women with such a history, even early in life.²⁸

Although several new risk factors for stroke at young age have been identified over the past decade, further research is needed to validate these emerging risk factors and uncover others that have yet not been determined, paving the way for improved prevention and early intervention strategies.

Defining stroke etiology: diagnostic approach

The diagnostic workup in young adults with ischemic stroke is generally more comprehensive than in older patients, reflecting the broad spectrum of potential underlying causes. However, as demonstrated by the JACARANDA study, standardized and comprehensive diagnostic protocols are not yet implemented globally, resulting in etiological subgroups that may be difficult to compare across populations.¹⁷

The diagnostic workup can be approached systematically using an “ABC” framework, focusing on three key components: arteries, blood, and cardiac function. The accompanying flowchart (Figure 1) provides guidance for clinicians in practice.

Figure 1.

Diagnostic flowchart for young patients with ischemic stroke.

Evaluation begins with neuroimaging, with MRI preferred due to its higher sensitivity in revealing ischemic patterns and its enhanced accuracy in detecting additional vascular brain damage compared to CT. Imaging of cervical (and intracranial) vessels is essential to identify atherosclerosis, arterial dissection or other arteriopathies that could potentially cause ischemic stroke.

Standard laboratory assessments include complete blood count (CBC), inflammatory markers, as well as lipid profile, fasting glucose and HbA1c to detect modifiable risk factors. Screening for antiphospholipid syndrome (APS) is recommended among selected patients, specifically those with a low cardiovascular risk profile. The updated diagnostic criteria from the American College of Rheumatology (ACR) and the European Alliance of Associations for Rheumatology (EULAR) highlight the importance of integrating clinical features with specific laboratory findings in the diagnostic evaluation of APS.³⁰ Thus, APS testing should be considered only in selected cases with a low cardiovascular risk profile and no other determined cause of stroke.

Cardiac evaluation is a key component of the diagnostic process and includes electrocardiography and rhythm monitoring to detect arrhythmias such as atrial fibrillation, along with transthoracic echocardiography (TTE), to identify structural abnormalities including a patent foramen ovale (PFO) and atrial septal aneurysm (ASA). A contrast-enhanced TTE is recommended unless an underlying cause has already been identified during the acute diagnostic phase (e.g. arterial dissection). A PFO may be a cause of ischemic stroke in a subset of patients via the process of paradoxical embolism. However, given its high prevalence—approximately 25% in the general population—determining its causal relation might be challenging. In general, PFO closure should be considered only in patients without another evident cause of stroke. The decision should be made in a multidisciplinary setting, guided by risk stratification tools such as the Risk of Paradoxical Embolism (RoPE) score and PFO-Associated Stroke Causal Likelihood (PASCAL) classification, as the benefit of closure varies substantially between individuals.²⁹

Long-term prognosis

Mortality

Mortality among young adults (18–49 years) with ischemic stroke is generally low, especially when compared to older populations. The highest risk of death occurs within the first year following the event (2.4%), with 10-year mortality rates ranging from 5.5% to 16%, approximately half of which are attributable to vascular causes.^31–33 While several epidemiologic studies have reported declining mortality rates over time, others suggest that case fatality has plateaued.^34–36 In this issue, Wang et al.³⁷ present data on childhood and adolescent stroke (both ischemic stroke and intracerebral hemorrhage) mortality in China between 2005 and 2020, demonstrating an overall decline over time. Notably, males showed higher 15-year mortality and years of life lost (YLL) than females, and a rise in stroke mortality was observed in the 15–19 age group.

The general decrease in pediatric stroke case fatality may reflect greater understanding of pathophysiological mechanisms and improved acute and long-term stroke care. The observed sex disparity in pediatric stroke incidence and mortality, with higher rates in males, has led to the exploration of several underlying biological and environmental factors. Possible explanations are elevated testosterone levels that might contribute to the increased risk of ischemic stroke and higher incidence of trauma with subsequent risk for arterial dissection.^38–41

Recurrence risk

The risk of recurrent (ischemic) stroke in young adults has been examined in several large cohorts across different regions.^42–46 In this issue of IJS, Kwok et al.⁴⁷ present a comprehensive overview of long-term recurrence risk in this population through their systematic review and meta-analysis, pooling global data to provide robust estimates of recurrence. They report cumulative stroke recurrence rates of 3–7% within the first year, 11–13% at 5 years, and 14–20% at 10 years. Although these rates are lower than those observed in older populations, they still represent a substantial long-term burden of disease for young stroke survivors.^48–50

Recurrence risk varies by stroke etiology, with the highest rates in patients with large artery atherosclerosis and the lowest in those with other determined etiology including arterial dissection, malignancy-associated thrombosis, APS, and Fabry disease, as observed in the analysis by Kwok et al. Grouping these diverse causes into a single category may lead to inaccurate prognostic interpretation, as they differ substantially in their outcomes.^51,52 To accurately assess outcomes in these specific etiologies, a more refined classification model may be needed.

Notably, patients with undetermined etiology (according to the TOAST classification), including those with ⩾2 likely causes, negative or incomplete evaluation (with no details reported on the extent of the diagnostic workup), had a 12-month recurrence rate of approximately 13% in the pooled analyses by Kwok et al., which was lowest among all etiological subtypes. In contrast, lower rates have been reported in well-characterized European cohorts with 5-year follow-up (6–9%), likely reflecting more thorough diagnostic evaluations and stricter etiologic classifications.^42,43

Hypertension, diabetes mellitus and a history of prior stroke or transient ischemic attack (TIA) emerged as predictors of recurrence, emphasizing the importance of early identification and optimal management of vascular risk factors. Although treatment of vascular risk factors in young adults often follows recommendations derived from studies in older populations, it is unclear whether these strategies can be directly extrapolated to younger patients. This highlights the importance of conducting research specifically focused on secondary prevention in this population.

Functional outcome

Young adults who experience an ischemic stroke generally have favorable functional outcomes. Many show only mild neurological deficits on the National Institutes of Health Stroke Scale (NIHSS) or minimal disability on the modified Rankin Scale (mRS).⁵³ In this issue of IJS, Pinter et al.⁵⁴ report that nearly 75% of study participants maintained an excellent functional outcome (mRS 0–1, indicating no significant disability) at a median follow-up of 10.4 years. Nevertheless, despite generally good outcomes in terms of physical recovery, the long-term symptom burden remains high.^46,55

Psychosocial consequences

Beyond physical disability, young stroke survivors frequently experience long-lasting psychosocial symptoms that significantly impact daily functioning and quality of life. Approximately half of the young ischemic stroke patients develop cognitive impairment, often with little to no improvement over the first year post-stroke.^4,56 In addition, fatigue, depression, and anxiety are also commonly reported among young stroke survivors.^5,6,57,58 In this issue, Pinter et al.⁵⁴ report on long-term non-motor outcomes after ischemic stroke or TIA at young age, with a median follow-up of 10.4 years. Cognitive impairment was present in 27.2%, fatigue in 27.6%, anxiety in 38%, and depression in 18.5%, with the latter three symptoms occurring more often in women. Notably, these symptoms were frequently reported even among patients with excellent functional recovery (mRS 0–1). The proportion of patients who successfully returned to work was 68%, consistent with previous findings.⁸ Cognitive impairment, poorer functional outcome, higher age, and lower educational level were associated with a reduced likelihood of returning to work.

These findings underscore the importance of recognizing and addressing psychosocial sequelae in young stroke survivors, to provide these patients adequate support and improve long-term outcomes.

Future directions and current research

Future research in young-onset ischemic stroke should aim to identify additional trigger factors as well as develop prognostic tools to estimate individual recurrence risk and guide secondary prevention strategies.

Significant progress has been made in understanding the epidemiology and risk factors of ischemic stroke in young adults, yet several important areas warrant further investigation.^23,53,59 As the incidence of stroke in this population is expected to rise, there is a need for greater awareness and advanced primary prevention strategies targeting known risk factors. In parallel, the identification of novel, potentially modifiable risk factors that may contribute to stroke but are not yet well recognized, remains essential. The SECRETO (Searching for Explanations for Cryptogenic Stroke in the Young: Revealing the Etiology, Triggers, and Outcome) study aims to address these topics, with a particular focus on patients with ischemic stroke of unknown cause (ClinicalTrials.gov ID: NCT01934725). By examining novel triggers, risk factors, genetic background, and long-term prognosis, this multicenter study strives to advance our understanding of the disease.⁶⁰

An equally important but still underexplored research area is the management of persistent psychosocial symptoms, as effective interventions could improve prognosis and help patients regain their previous level of functioning.

Improving prognostic tools and optimizing long-term management according to stroke etiology remain important topics for future study as well, as outcomes vary significantly across etiologic subtypes. A particularly unresolved issue is the optimal duration of antiplatelet therapy in young patients with cryptogenic stroke. Findings from a Dutch cohort indicate that recurrence risk declines substantially after 2–5 years, raising questions about the need for long-term antiplatelet therapy, especially since one in five young patients experience a bleeding event requiring medical attention within 10 years after the initiation of antiplatelet therapy.^42,61 To address this issue, the multicenter STOP trial (STopping Or continuing Platelet inhibitors after cryptogenic stroke at young age) has been launched in the Netherlands (ISRCTN96178713). This randomized clinical trial aims to determine whether discontinuation of antiplatelet therapy, at least 3 years after a cryptogenic stroke at young age, is non-inferior to continued treatment in preventing recurrent vascular events. Study completion is expected in 2032.

Another key issue regarding secondary prevention after ischemic stroke at young age is the optimal duration of antithrombotic therapy after PFO closure in cryptogenic stroke. Current European guidelines recommend dual antiplatelet therapy for 1 to 6 months after PFO closure, followed by single antiplatelet therapy for at least 5 years.⁶² However, it is well established that the recurrence rate after cryptogenic stroke and PFO closure is low. A recently published study from an Austrian cohort reports a recurrence rate of 0.38 per 100 patient-years over a median follow-up of 10 years, which aligns with earlier studies, though those had shorter follow-up durations.^63–66 As earlier mentioned, prolonged antithrombotic use increases the risk of bleeding.^61,66 To evaluate whether the benefit of prolonged antithrombotic therapy outweighs the bleeding risks, the HALTI trial (Discontinuation of Antithrombotic Treatment Following Patent Foramen Ovale Closure in Young Patients With Cryptogenic Stroke) was initiated in 2020 to investigate whether antithrombotic therapy can safely be stopped 12 months after PFO closure in young patients with cryptogenic stroke (ClinicalTrials.gov ID: NCT04475510). The study is currently still recruiting participants, with the study completion estimated in 2032.

Conclusion

The rising incidence of ischemic stroke in young adults is an alarming trend that calls for deeper insights into its underlying trigger factors and mechanisms. Although substantial progress has been made in identifying novel risk factors, future research should aim to uncover additional contributors that lead to an increased risk of cerebrovascular events in this age group. Given the considerable long-term impact on psychosocial functioning, healthcare systems must be organized to ensure adequate follow-up and treatment for persistent post-stroke symptoms. Furthermore, as recurrence risk differs by stroke etiology, there is need for individualized prognostic tools to guide more risk-adapted secondary prevention strategies.

This issue of IJS presents some interesting work that contributes to a better understanding of the epidemiology, risk factors, and prognosis of stroke in the young.

Footnotes

Declaration of conflicting interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

ORCID iD

A Rasing

References

Scott

Rothwell

PM.

Diverging temporal trends in stroke incidence in younger vs older people: a systematic review and meta-analysis. JAMA Neurol 2022; 79: 1036–1048.

Cabral

Freire

Conforto

, et al. Increase of stroke incidence in young adults in a middle-income country: a 10-year population-based study. Stroke 2017; 48: 2925–2930.

Ning

Sun

Jiang

, et al. Increased stroke burdens among the low-income young and middle aged in rural China. Stroke 2017; 48: 77–83.

Schellekens

Springer

Boot

, et al. Cognitive trajectory in the first year after first-ever ischaemic stroke in young adults: the ODYSSEY study. J Neurol Neurosurg Psychiatry 2024; 95: 571–579.

Maaijwee

Arntz

Rutten-Jacobs

, et al. Post-stroke fatigue and its association with poor functional outcome after stroke in young adults. J Neurol Neurosurg Psychiatry 2015; 86: 1120–1126.

Maaijwee

Tendolkar

Rutten-Jacobs

, et al. Long-term depressive symptoms and anxiety after transient ischaemic attack or ischaemic stroke in young adults. Eur J Neurol 2016; 23: 1262–1268.

Schellekens

Boot

Verhoeven

, et al. Cognitive performance is associated with return to work after ischemic stroke in young adults: the ODYSSEY study. Eur Stroke J 2025; 10: 784–795.

Edwards

Kapoor

Linkewich

, et al. Return to work after young stroke: a systematic review. Int J Stroke 2018; 13: 243–256.

Scott

Rothwell

PM.

Association of younger vs older ages with changes in incidence of stroke and other vascular events, 2002-2018. JAMA 2022; 328: 563–574.

10.

Global regional national burden of stroke its risk factors. 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol 2021; 20: 795–820.

11.

Nehme

. The rising incidence of stroke in the young: epidemiology, causes and global impact. Int J Stroke 2025; 21: 14–23.

12.

Minelli

Cabral

Ujikawa

, et al. Trends in the incidence and mortality of stroke in Matão, Brazil: the Matão Preventing Stroke (MAPS) study. Neuroepidemiology 2020; 54: 75–82.

13.

Kõrv

Vibo

Kõrv

Declining first-ever stroke incidence rates in 15- to 54-year-old residents of Tartu, Estonia, from 1991 to 2017. Int J Stroke 2023; 18: 462–468.

14.

George

Tong

Bowman

BA.

Prevalence of cardiovascular risk factors and strokes in younger adults. JAMA Neurol 2017; 74: 695–703.

15.

Biesbroek

Niesten

Dankbaar

, et al. Diagnostic accuracy of CT perfusion imaging for detecting acute ischemic stroke: a systematic review and meta-analysis. Cerebrovasc Dis 2013; 35: 493–501.

16.

Edlow

Hurwitz

Edlow

JA.

Diagnosis of DWI-negative acute ischemic stroke: a meta-analysis. Neurology 2017; 89: 256–262.

17.

Gonzalez

López

Tamagnini

, et al. Young adults with ischemic stroke in Argentina: a national multicenter retrospective registry analysis (JACARANDA). Int J Stroke 2025: 17474930251378281.

18.

Aigner

Grittner

Rolfs

Norrving

Siegerink

Busch

MA.

Contribution of established stroke risk factors to the burden of stroke in young adults. Stroke 2017; 48: 1744–1751.

19.

Shoskes

Zhou

Ying

, et al. Temporal trends in vascular risk factor burden among young adults with ischemic stroke: the Florida stroke registry. Neurology 2025; 104: e213447.

20.

Hystad

Larkin

Rangarajan

, et al. Associations of outdoor fine particulate air pollution and cardiovascular disease in 157 436 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet Planet Health 2020; 4: e235–e245.

21.

Yitshak Sade

Novack

Ifergane

Horev

Kloog

. Air pollution and ischemic stroke among young adults. Stroke 2015; 46: 3348–3353.

22.

Verhoeven

Allach

Vaartjes

ICH

Klijn

CJM

de Leeuw

FE.

Ambient air pollution and the risk of ischaemic and haemorrhagic stroke. Lancet Planet Health 2021; 5: e542–e552.

23.

Ekker

Verhoeven

Rensink

, et al. Trigger factors for stroke in young adults: a case-crossover study. Neurology 2023; 100: e49–e61.

24.

Westover

McBride

Haley

RW.

Stroke in young adults who abuse amphetamines or cocaine: a population-based study of hospitalized patients. Arch Gen Psychiatry 2007; 64: 495–502.

25.

Ferro

Massaro

Mas

JL.

Aetiological diagnosis of ischaemic stroke in young adults. Lancet Neurol 2010; 9: 1085–1096.

26.

Deb

Vasireddi

Bhatia

, et al. Non-cardiac and cardiac risk for ischemic stroke in young adults: the Stanford Y-CORE (Young cardiovascular outcomes and risk evaluation) study. Int J Stroke 2025: 17474930251338611.

27.

Verhoeven

Fan

Broeders

MJM

, et al. Association of stroke at young age with new cancer in the years after stroke among patients in the Netherlands. JAMA Netw Open 2023; 6: e235002.

28.

Verburgt

Hilkens

Verhoeven

, et al. History of pregnancy complications and the risk of ischemic stroke in young women. Neurology 2025; 105: e214009.

29.

Kent

Saver

Kasner

, et al. Heterogeneity of treatment effects in an analysis of pooled individual patient data from randomized trials of device closure of patent foramen ovale after stroke. JAMA 2021; 326: 2277–2286.

30.

Barbhaiya

Zuily

Naden

, et al. 2023 ACR/EULAR antiphospholipid syndrome classification criteria. Ann Rheum Dis 2023; 82: 1258–1270.

31.

Broman

Fandler-Höfler

von Sarnowski

, et al. Long-term risk of recurrent vascular events and mortality in young stroke patients: insights from a multicenter study. Eur J Neurol 2023; 30: 2675–2683.

32.

Aarnio

Haapaniemi

Melkas

Kaste

Tatlisumak

Putaala

Long-term mortality after first-ever and recurrent stroke in young adults. Stroke 2014; 45: 2670–2676.

33.

Rutten-Jacobs

Arntz

Maaijwee

, et al. Long-term mortality after stroke among adults aged 18 to 50 years. JAMA 2013; 309: 1136–1144.

34.

Seminog

Scarborough

Wright

Rayner

Goldacre

MJ.

Determinants of the decline in mortality from acute stroke in England: linked national database study of 795 869 adults. BMJ 2019; 365: l1778.

35.

Bejot

Rouaud

Durier

, et al. Decrease in the stroke case fatality rates in a French population-based twenty-year study. A comparison between men and women. Cerebrovasc Dis 2007; 24: 439–444.

36.

Kim

Kang

, et al. Improvement in delivery of ischemic stroke treatments but stagnation of clinical outcomes in young adults in South Korea. Stroke 2023; 54: 3002–3011.

37.

Wang

Long

, et al. National and provincial trends of mortality and years of life lost due to stroke in children and adolescents in China, 2005-2020: an analysis of national mortality surveillance data. Int J Stroke 2025: 17474930251360105.

38.

Steinberg

Brandel

Kang

, et al. Arteriovenous malformation surgery in children: the Rady Children’s Hospital experience (2002-2019). Childs Nerv Syst 2021; 37: 1267–1277.

39.

Qureshi

Muthusami

Krings

, et al. Clinical and angioarchitectural features of hemorrhagic brain arterio-venous malformations in adults and children: contrasts and implications on outcome. Neurosurgery 2021; 89: 645–652.

40.

Normann

de Veber

Fobker

, et al. Role of endogenous testosterone concentration in pediatric stroke. Ann Neurol 2009; 66: 754–758.

41.

Golomb

Fullerton

Nowak-Gottl

Deveber

. International Pediatric Stroke Study Group. Male predominance in childhood ischemic stroke: findings from the international pediatric stroke study. Stroke 2009; 40: 52–57.

42.

Verburgt

Hilkens

Ekker

, et al. Short-term and long-term risk of recurrent vascular event by cause after ischemic stroke in young adults. JAMA Netw Open 2024; 7: e240054.

43.

Putaala

Haapaniemi

Metso

, et al. Recurrent ischemic events in young adults after first-ever ischemic stroke. Ann Neurol 2010; 68: 661–671.

44.

Arauz

Murillo

Márquez

, et al. Long-term risk of recurrent stroke in young cryptogenic stroke patients with and without patent foramen ovale. Int J Stroke 2012; 7: 631–634.

45.

Leys

Bandu

Hénon

, et al. Clinical outcome in 287 consecutive young adults (15 to 45 years) with ischemic stroke. Neurology 2002; 59: 26–33.

46.

Varona

Bermejo

Guerra

Molina

JA.

Long-term prognosis of ischemic stroke in young adults. Study of 272 Cases. J Neurol 2004; 251: 1507–1514.

47.

Kwok

GYR

Chen

RWR

Leow

, et al. Recurrent ischaemic stroke in young adults: a multi-centre cohort study, systematic review and meta-analysis. Int J Stroke 2025: 17474930251340799.

48.

Khan

Yogendrakumar

Lun

, et al. Long-term risk of stroke after transient ischemic attack or minor stroke: a systematic review and meta-analysis. JAMA 2025; 333: 1508–1519.

49.

Lin

Zhang

Mei

, et al. Cumulative risk of stroke recurrence over the last 10 years: a systematic review and meta-analysis. Neurol Sci 2021; 42: 61–71.

50.

Mohan

Wolfe

Rudd

, et al. Risk and cumulative risk of stroke recurrence: a systematic review and meta-analysis. Stroke 2011; 42: 1489–1494.

51.

Zhao

Zhou

, et al. Was antiphospholipid syndrome a risk factor of stroke? A systemic review and meta-analysis of cohort studies. Dis Markers 2021; 2021: 4431907.

52.

Pezzini

Grassi

Zedde

, et al. Antithrombotic therapy in the postacute phase of cervical artery dissection: the Italian project on stroke in young adults cervical artery dissection. J Neurol Neurosurg Psychiatry 2022; 93: 686–692.

53.

Ekker

Verhoeven

Schellekens

MMI

, et al. Risk factors and causes of ischemic stroke in 1322 young adults. Stroke 2023; 54: 439–447.

54.

Pinter

Broman

Leitner

, et al. Long-term outcome of young patients after ischemic stroke or transient ischemic attack: insights from a multicenter study. Int J Stroke 2025: 17474930251359422.

55.

Maaijwee

Rutten-Jacobs

Schaapsmeerders

van Dijk

de Leeuw

FE.

Ischaemic stroke in young adults: risk factors and long-term consequences. Nat Rev Neurol 2014; 10: 315–325.

56.

Weterings

Kessels

de Leeuw

Piai

Cognitive impairment after a stroke in young adults: a systematic review and meta-analysis. Int J Stroke 2023; 18: 888–897.

57.

Ozkan

Ambler

Esmail

Banerjee

Simister

Werring

DJ.

Prevalence, trajectory, and factors associated with patient-reported non-motor outcomes after stroke: a systematic review and meta-analysis. JAMA Netw Open 2025; 8: e2457447.

58.

Ignacio

KHD

Muir

Diestro

JDB

, et al. Prevalence of depression and anxiety symptoms after stroke in young adults: a systematic review and meta-analysis. J Stroke Cerebrovasc Dis 2024; 33: 107732.

59.

George

MG.

Risk factors for ischemic stroke in younger adults: a focused update. Stroke 2020; 51: 729–735.

60.

Putaala

Martinez-Majander

Saeed

, et al. Searching for explanations for cryptogenic stroke in the young: revealing the triggers, causes, and outcome (SECRETO): rationale and design. Eur Stroke J 2017; 2: 116–125.

61.

Verhoeven

van Lith

Ekker

, et al. Long-term risk of bleeding and ischemic events after ischemic stroke or transient ischemic attack in young adults. Neurology 2022; 99: e549–e59.

62.

Caso

Turc

Abdul-Rahim

, et al. European Stroke Organisation (ESO) Guidelines on the diagnosis and management of patent foramen ovale (PFO) after stroke. Eur Stroke J 2024; 9: 800–834.

63.

Goessinger

Greisenegger

Kastl

, et al. Stroke recurrence after transcatheter PFO closure in patients with cryptogenic stroke. Int J Stroke 2025; 20: 450–460.

64.

Saver

Carroll

Thaler

, et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med 2017; 377: 1022–1032.

65.

Søndergaard

Kasner

Rhodes

, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med 2017; 377: 1033–1042.

66.

Wintzer-Wehekind

Alperi

Houde

, et al. Impact of discontinuation of antithrombotic therapy following closure of patent foramen ovale in patients with cryptogenic embolism. Am J Cardiol 2019; 123: 1538–1545.